Here's Some NEW'S Just Out This Morning From VGX Site
VGX 200 VGX Inter, according to the license agreement with Roche royalties and more than 20 billion won a separate cash inflows expected
ADMIN ADMIN 2013.09.11 18:41 09/11/2013 18:41 8 8
VGX 인터 (KOSPI:011000) VGX Inter (KOSPI: 011000) today, "the last 10 days due to the license agreement with Roche Inovio DNA vaccine and hepatitis B-related milestone amount to more than 20 billion won 만 cash inflows are expected when the product is commercialized worldwide product sales for a certain percentage of the royalty income is expected, "he said.
In early September is expected to receive a down payment, according to the milestones that further explain the influx is about 200 billion. Separately, the global hepatitis B market ranging from about 4 trillion Given that a significant amount of product sales, royalties based on The larger the company is expected to occur. B 1 8,000 . One great way of hepatitis B therapeutics market sales of Viread rear Prio Inc billion more than the year 8000.
. In addition, the company with manufacturing facilities in the United States in Houston CMO DNA vaccine and the hepatitis B DNA vaccine treatment of prostate cancer, non-clinical sample said it is in talks to supply.
VGX 인터가 보유한 DNA Geumbeon multinational Inovio's license agreement with Roche Roche beolyeotgo due diligence by dispatching experts from Inovio and VGX Inter held by a DNA vaccine technology and production facilities to verify the superiority of the back door because is was possible.
. Have deep pockets and vast distribution network is a global pharmaceutical company Roche Top5 (based on 2012 sales of $ 37.5 billion, 37 trillion won), a DNA vaccine pipeline, adding that much of the success potential of DNA vaccines are more likely to ensure that due hayeotgi Experts are reported. Roche As a partner in the development of DNA vaccines for the global pharmaceutical drug development know-how are combined DNA vaccine development period